4月14日 - ** 制药公司百健BIIB.O股价上涨2.8%至118.42美元
** BIIB称 (link)，欧盟执委会正在对该公司阿尔茨海默氏症药物lecanemab的上市许可申请做出最终决定。
** 这一最新消息是在 2025 年 2 月人用药产品委员会$(CHMP)$ 重新确认 (link) 对该药物批准的积极意见之后发布的。
** 该疗法已在美国和许多其他国家获得批准，它将成为欧洲首个获批的直接治疗神经退行性疾病的药物，而不仅仅是治疗其症状。
** 截至上次收盘，该公司股价已累计下跌 23.1
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.